Collegium Pharmaceutical (NASDAQ:COLL) Upgraded to “Strong-Buy” at Truist Financial

Truist Financial upgraded shares of Collegium Pharmaceutical (NASDAQ:COLL) to a strong-buy rating in a report released on Monday morning,Zacks.com reports.

A number of other research analysts have also weighed in on COLL. Needham & Company LLC reissued a “buy” rating and issued a $56.00 target price (up from $54.00) on shares of Collegium Pharmaceutical in a report on Thursday, March 19th. HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, March 20th. Weiss Ratings lowered shares of Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, March 5th. Finally, Wall Street Zen raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, Collegium Pharmaceutical presently has an average rating of “Moderate Buy” and an average price target of $57.50.

Collegium Pharmaceutical Trading Down 1.3%

Shares of COLL stock opened at $34.19 on Monday. Collegium Pharmaceutical has a 12-month low of $29.11 and a 12-month high of $50.79. The company has a current ratio of 1.71, a quick ratio of 1.62 and a debt-to-equity ratio of 2.47. The stock’s 50-day moving average price is $34.03 and its 200-day moving average price is $40.42. The stock has a market capitalization of $1.11 billion, a price-to-earnings ratio of 16.76 and a beta of 0.75.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 EPS for the quarter, topping analysts’ consensus estimates of $1.52 by $0.24. The company had revenue of $193.52 million for the quarter, compared to the consensus estimate of $184.47 million. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.The firm’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same period in the previous year, the business earned $1.49 earnings per share. Equities research analysts predict that Collegium Pharmaceutical will post 6.76 EPS for the current fiscal year.

Insider Transactions at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP David Dieter sold 13,976 shares of the firm’s stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $34.92, for a total transaction of $488,041.92. Following the completion of the transaction, the executive vice president directly owned 77,071 shares of the company’s stock, valued at approximately $2,691,319.32. This trade represents a 15.35% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 1.85% of the company’s stock.

Institutional Trading of Collegium Pharmaceutical

A number of hedge funds and other institutional investors have recently made changes to their positions in COLL. Group One Trading LLC purchased a new position in shares of Collegium Pharmaceutical during the fourth quarter worth $28,000. Caitong International Asset Management Co. Ltd boosted its holdings in Collegium Pharmaceutical by 205.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock valued at $29,000 after purchasing an additional 427 shares during the last quarter. PNC Financial Services Group Inc. grew its position in Collegium Pharmaceutical by 42.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock worth $47,000 after purchasing an additional 418 shares during the period. Kemnay Advisory Services Inc. acquired a new stake in Collegium Pharmaceutical during the 4th quarter worth about $61,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Collegium Pharmaceutical by 26.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock valued at $71,000 after buying an additional 318 shares during the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.